Results 121 to 130 of about 94,483 (313)

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

The Bulletin: Sidney Kimmel Medical College at Thomas Jefferson University, Volume 65, Issue 4, Fall 2016 [PDF]

, 2016
This issue includes: Creating the Ideal Physician-One Note at a Time: The Dean\u27s concert series is more than a respite in the middle of a busy day at SKMC Tiny Bubbles, Big Future: New uses for microbubble-filled ultrasound contrast agents could ...

core   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Nebivolol-induced hepatoxicity: a case report

European Journal of Case Reports in Internal Medicine
Nebivolol is a third-generation beta-blocker known for its high selectivity for beta-1 adrenergic receptors and its unique ability to induce vasodilation via nitric oxide (NO) release.
Lynn Srour, Majed Ali, Karam Karam, Elias Fiani   +3 more
doaj   +1 more source

Beta‐blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes

European Journal of Heart Failure, EarlyView.
In total, 5084 patients from Swedish registries with both heart failure (HF) with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) were included. Confounding was handled by overlap weighting based on propensity scores for beta‐blocker use. Patients were followed up for 5 years, or until death, emigration from Sweden or
Benedikt N. Beer, Lina Benson, Christian Basile, Benedikt Schrage, Peter Moritz Becher, Stefan Blankenberg, Paulus Kirchhof, Barna Szabó‐Söderberg, Marco Metra, Anne Lindberg, Egidio Imbalzano, Giuseppe M. C. Rosano, Patric Karlström, Peter G.M. Mol, Raffaele Scorza, Lars H. Lund, Felix Lindberg, Gianluigi Savarese   +17 more
wiley   +1 more source

European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action

European Journal of Heart Failure, EarlyView.
Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non‐adherence and side effects.
Mark Luedde, Stefan Agewall, Giuseppe Ambrosio, Antoni Bayes‐Genis, Claudio Borghi, Elisabetta Cerbai, Gheorghe A. Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Juan Carlos Kaski, Roland Klingenberg, Joao Morais, William Parker, Mark C. Petrie, Bianca Rocca, Anne Grete Semb, Michele Senni, Christian Sohns, Patrick Sulzgruber, Juan Tamargo, Marco Metra, Michael Böhm, Dobromir Dobrev, Samuel Sossalla   +24 more
wiley   +1 more source

Imipramine Increases Norepinephrine and Serotonin in the Salivary Glands of Rats

Biology
Xerostomia induced by antidepressants such as imipramine has long been thought to be due to their anticholinergic effects. However, even antidepressants with low anticholinergic effects may have a high incidence of xerostomia.
Kosuke Shirose, Masanobu Yoshikawa, Takugi Kan, Masaaki Miura, Mariko Watanabe, Mitsumasa Matsuda, Hiroyuki Kobayashi, Mitsuru Kawaguchi, Kenji Ito, Takeshi Suzuki   +9 more
doaj   +1 more source

Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
Main categories of harmful drugs in heart failure. CCB, calcium channel blocker; DPP4i, dipeptidyl peptidase‐4 inhibitor; HER2‐TT, human epidermal growth factor receptor 2‐targeted therapy; NSAID, non‐steroidal anti‐inflammatory drug; TKI, tyrosine kinase inhibitor; TZD, thiazolidinedione; VEGF Inh, vascular endothelial growth factor inhibitor.
Amr Abdin, Johann Bauersachs, Magdy Abdelhamid, Suleman Aktaa, Hussam Al Ghorani, Antonio Bayes‐Genis, Jan Biegus, Michael Böhm, Javed Butler, Nicolas Girerd, Marco Metra, Wilfried Mullens, Hadi Skouri, Muthiah Vaduganathan, Seif El Hadidi, Giuseppe M.C. Rosano, Gianluigi Savarese   +16 more
wiley   +1 more source

PEG-coated gold nanoparticles attenuate β-adrenergic receptor-mediated cardiac hypertrophy

International Journal of Nanomedicine, 2017
Yuhui Qiao, Baoling Zhu, Aiju Tian, Zijian Li Department of Cardiology, Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of ...
Qiao YH, Zhu BL, Tian AJ, Li ZJ
doaj